A 59-year-old man with progressive and advanced agnogenic myeloid metaplasia, also called idiopathic myelofibrosis, had complications showing bilateral interstitial pneumonic shadows. Pathological assessment of transbronchial biopsy revealed pulmonary perivascular fibrosis and infiltration of megakaryocytes. Autopsy 3 months later showed extramedullary megakaryopoiesis and fibrosis in lung, pleura, kidney, liver and spleen. Histopathological analysis for platelet-derived growth factor (PDGF) and PDGF-receptor revealed an abnormally high expression of the PDGF-receptor-β gene in pulmonary fibroblasts. This is the first description of an association between pulmonary fibrosis and PDGF in idiopathic myelofibrosis.

1.
Kahn A, Bernard JF, Cottreau D, Marie J, Bovin P: A deficient G-6-PD variant with hemizygous expression in blood cells of a woman with primary myelofibrosis. Humangenetik 1975;30:41–46.
2.
Jacobson RJ, Salo A, Fialkow PJ: Agnogenic myeloid metaplasia: A clonal proliferation of hematopoietic stem cells with secondary myelofibrosis. Blood 1978;51:189–194.
3.
Lieberman PH, Rosvoll RV, Ley AB: Extramedullary myeloid tumors in primary myelofibrosis. Cancer 1965;18:727–736.
4.
Hino S, Fukui K: Primary myelofibrosis associated with marked pulmonary fibrosis and hematopoiesis: Report of a case. Jpn J Clin Hematol 1973;14:1426–1433.
5.
Glew RH, Haese WH, McIntyre PA: Myeloid metaplasia with myelofibrosis: The clinical spectrum of extramedullary hematopoiesis and tumor formation. Johns Hopkins Med J 1973;132:253–270.
6.
Kataoka T, Sayama H, Watanabe E, Yano K, Satake T: A case of primary myelofibrosis with nephrotic syndrome and pulmonary fibrosis terminating in acute leukemia. Jpn J Clin Hematol 1985;26:985–990.
7.
Asakura S, Colby TV: Agnogenic myeloid metaplasia with extramedullary hematopoiesis and fibrosis in the lung: Report of two cases. Chest 1994;105:1866–1868.
8.
Coates GG, Eisenberg B, Dail DH: Tc-99m sulufur colloid demonstration of diffuse pulmonary interstitial extramedullary hematopoiesis in a patient with myelofibrosis. Clin Nucl Med 1994;19:1079–1084.
9.
Yusen RD, Kollef MH: Acute respiratory failure due to extramedullary hematopoiesis. Chest 1995;108:1170–1172.
10.
Pitcock JA, Reinhard EH, Justus BW, Mendelsohn RS: A clinical and pathological study of seventy cases of myelofibrosis. Ann Intern Med 1962;57:73–84.
11.
Thiele J, Kvasnicka HM, Diehl V, Fischer R, Michiels JJ: Clinicopathological diagnosis and differential criteria of thrombocythemias in various myeloproliferative disorders by histopathology, histochemistry and immunostaining bone marrow biopsies. Leuk Lymphoma 1999;33:207–218.
12.
Thiele J, Kvasnicka HM, Fischer R: Histochemistry and morphometry on bone marrow biopsies in chronic myeloproliferative disorders: Aids to diagnosis and classification. Ann Hematol 1999;78:495–506.
13.
Michiels JJ, Kutti J, Stark P, Bazzan M, Gugliotta L, Marchioli R, Griesshammer M, van Genderen PJJ, Briere J, Kiladjian JJ, Barbui T, Finazzi G, Berlin NI, Pearson TC, Green AC, Fruchtmann SM, Silver RT, Hansmann E, Wehmeier A, Lengfelder E, Laudolfi R, Kvasnicka HM, Hasselbalch H, Cervantes F, Reilly JT, Demory JL, Gisslinger H, Guardiola Ph, Martyre MC, Le Bousse-Kerdiles MC, Thiele J: Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis. Netherland J Med 1999;54:46–62.
14.
Fujii H, Kitazawa R, Maeda S, Mizuno K, Kitazawa S: Expression of platelet-derived growth factor proteins and their receptor-α and β mRNAs during fracture healing in the normal mouse. Histochem Cell Biol 1999;112:131–138.
15.
Kitazawa S, Kitazawa R, Maeda S: In situ hybridization with polymerase chain reaction-derived single-stranded DNA probe and S1 nuclease. Histochem Cell Biol 1999;111:7–12.
16.
Martyre MC, Le Bousse-Kerdiles MC, Romquin N, Chevillard S, Praloran V, Demory JL, Dupriez B: Elevated levels of basic fibroblast growth factor in megakaryocytes and platelets from patients with idiopathic myelofibrosis. Br J Haematol 1997;97:441–448.
17.
Martyre MC: TGF-β and megakaryocytes in the pathogenesis of myelofibrosis in myeloproliferative disorders. Leuk Lymphoma 1995;20:39–44.
18.
Katoh O, Kimura A, Itoh T, Kuramoto A: Platelet derived growth factor messenger RNA is increased in bone marrow megakaryocytes in patients with myeloproliferative disorders. Am J Hematol 1990;35:145–150.
19.
Martyre MC, Romquin N, Le Bousse-Kerdiles MC, Chevillard S, Benyahia B, Dupriez B, Demory JL, Bauters F: Transforming growth factor-β and megakaryocytes in the pathogenesis of idiopathic myelofibrosis. Br J Haematol 1994;88:9–16.
20.
Martyre MC: Platelet PDGF and TGF-β levels in myeloproliferative disorders. Leuk Lymphoma 1991;6:1–6.
21.
Reilly JT: Pathogenesis of idiopathic myelofibrosis: Role of growth factors. J Clin Pathol 1992;45:461–464.
22.
Le Bousse-Kerdiles MC, Martyre MC, Members of the French INSERM Research Network on Idiopathic Myelofibrosis: Dual implication of fibrogenic cytokines in the pathogenesis of fibrosis and myeloproliferation in myeloid metaplasia with myelofibrosis. Ann Hematol 1999;78:437–444.
23.
Homma S, Nagaoka Y, Abe H, Takahashi K, Seyama K, Nukiwa T, Kira S: Localization of platelet-derived growth factor and insulin-like growth factor I in the fibrotic lung. Am J Respir Crit Care Med 1995;152:2084–2089.
24.
Baglin TP, Price SM, Boughton BT: A reversible defect of platelet PDGF content in myeloproliferative disorders. Br J Haematol 1988;69:483–486.
25.
Bernabei PA, Arcangeli A, Casini M, Grossi A, Padovani R, Rossi-Ferrini P: Platelet-derived growth factor(s) mitogenic activity in patients with myeloproliferative disease. Br J Haematol 1986;63:353–357.
26.
Katoh O, Kimura A, Kuramoto A: Platelet-derived growth factor is decreased in patients with myeloproliferative disorders. Am J Hematol 1988;27:276–280.
27.
Romano M, Poggi A, Donati MB, Cortellazzo S, Viero P, Barbui T: Reduced platelet mitogenic activity in myeloproliferative disorders. Lancet 1986;ii:345.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.